Table 1 Basic demographics of the ALLIANCE cohort

N

86

106

41

Age (yrs)

56.2 ± 13.4

48.5 ± 13.0

46.3 ± 19.3

P  = 0.0001 ^a

Male

40 (47)

45 (42)

24 (59)

P  = 0.213 ^c

Body-mass-index

29.2 ± 6.9

26.8 ± 4.5

24.8 ± 3.9

P  < 0.0001 ^a

Current or former smoker ≥ 10PY

23(27)

28(26)

3(7)

P  = 0.030 ^c

Pack years (yrs)

6.9 ± 11.6

7.5 ± 13.6

1.4 ± 3.6

P  = 0.005 ^c

Blood Eosinophils

0.43 ± 0.3

0.38 ± 0.4

0.17 ± 0.1

P  < 0.0001 ^a

Blood Neutrophils

5.90 ± 2.8

4.00 ± 1.3

3.10 ± 1.0

P  < 0.0001 ^a

C1M ng/mL

41.0 ± 44.1

31.0 ± 21.1

24.1 ± 12.4

P  = 0.001 ^a

Clinical variables

  FEV1 (L)

2.2 ± 0.8

2.8 ± 0.7

3.7 ± 0.9

P  < 0.0001 ^a

  FEV1 (% predicted)

76.8 ± 21.4

94.0 ± 18.2

107.9 ± 10.1

P  < 0.0001 ^a

  FVC (L)

3.6 ± 1.0

4.1 ± 1.0

4.8 ± 1.1

P  < 0.0001 ^a

  FVC (% predicted)

97.8 ± 18.3

107.5 ± 15.5

113.6 ± 14.5

P  < 0.0001 ^a

  FEV1/FVC

0.60 ± 0.1

0.68 ± 0.1

0.76 ± 0.1

P  < 0.0001 ^a

  sReff (kPa*s/L)

1.8 ± 1.2

1.2 ± 0.8

0.8 ± 0.2

P  < 0.0001 ^a

  sReff (% predicted)

173.5 ± 118.9

116.2 ± 79.5

69.9 ± 20.1

P  < 0.0001 ^a

  R5Hz (kPa/l/s)

0.5 ± 0.2

0.5 ± 0.2

0.3 ± 0.1

P  < 0.0001 ^a

  ≥2 severe exacerbations in last 12 months

48(56)

19(18)

n/a

P  < 0.0001 ^c

Treatments

  ICS (µg/day fluticasone)

972.8 ± 492.6

302.0 ± 193.7

n/a

P  < 0.0001 ^b

  OCS

39 (45)

0

n/a